A Latent Pharmacokinetic Time Profile to Model Dose-Response Survival Data

By Jacobs Tom  

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 4, 2010-07 ,pp. : 759-767

Taylor & Francis Ltd

Access to resources Recommend Favorite

Discrete versus cumulative dosing in dose-response discrimination studies

By Schechter M.D.  

European Journal of Pharmacology, Vol. 326, Iss. 2, 1997-05 ,pp. : 113-118

Elsevier

Access to resources Recommend Favorite

The Maturing of Hormesis as a Credible Dose-Response Model

By Calabrese Edward J.  

Nonlinearity in Biology, Vol. 1, Iss. 3, 2003-07 ,pp. : 319-343

Taylor & Francis Ltd

Access to resources Recommend Favorite

Leukemia incidence of 96,000 Hiroshima atomic bomb survivors is compelling evidence that the LNT model is wrong: Edward Calabrese’s papers “Origin of the linear no threshold (LNT) dose-response concept” (Arch Toxicol (2013) 87:1621–1633) and “How the US National Academy of Sciences misled the world community on cancer risk assessment: new findings challenge historical foundations of the linear dose response” (Arch Toxicol (2013) 87:2063–2081)

By Cuttler Jerry  

Archives of Toxicology, Vol. 88, Iss. 3, 2014-03 ,pp. : 847-848

Springer Publishing Company

Access to resources Recommend Favorite

Design and Sample Size for Evaluating Combinations of Drugs of Linear and Loglinear Dose-Response Curves

By Fang Hong-Bin  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 625-640

Taylor & Francis Ltd

Access to resources Recommend Favorite